{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:00:13Z","timestamp":1791518413972,"version":"4.3.4"},"reference-count":101,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Chronic kidney disease (CKD) is a serious health issue with rising morbidity and mortality rates. Despite advances in understanding its pathophysiology, effective therapeutic options are limited, necessitating innovative treatment approaches. Also, current frontline treatments that are available against CKD are not uniformly effective and often come with significant side effects. Therefore, identifying new therapeutic targets or improving existing treatments for CKD is crucial. Drug repurposing is a promising strategy in the drug discovery process that involves screening existing approved drugs for new therapeutic applications.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key findings<\/jats:title>\n                  <jats:p>This review discusses the pharmacological mechanisms and clinical evidence that support the efficacy of these repurposed drugs. Various drugs classes such as inodilators, endothelin-1 type A (ET-1A) receptor antagonists, bisphosphonates, mineralocorticoid receptor (MR) antagonists, DNA demethylating agents, nuclear factor erythroid 2-related factor 2 (NRF2) activators, P2X7 inhibitors, autophagy modulators, hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHI) are discussed that could remarkably contribute against CKD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>The review critically examines the potential for repurposing well-established drugs to slow the progression of CKD and enhance patient outcomes. This review emphasizes the importance of a multidisciplinary approach in advancing the field of drug repurposing, ultimately paving the way for innovative and effective therapies for patients suffering from CKD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jpp\/rgaf002","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T19:59:48Z","timestamp":1737403188000},"page":"715-728","source":"Crossref","is-referenced-by-count":8,"title":["Repurposing the familiar: Future treatment options against chronic kidney disease"],"prefix":"10.1093","volume":"77","author":[{"given":"Rohan","family":"Bhadange","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Birla Institute of Technology and Science , Pilani, Pilani Campus, 333031, Rajasthan ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4627-5504","authenticated-orcid":false,"given":"Anil Bhanudas","family":"Gaikwad","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Birla Institute of Technology and Science , Pilani, Pilani Campus, 333031, Rajasthan ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"key":"2025060923364830800_CIT0001","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0140-6736(21)00519-5","article-title":"Chronic kidney disease","volume":"398","author":"Kalantar-Zadeh","year":"2021","journal-title":"Lancet"},{"key":"2025060923364830800_CIT0002","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1007\/s00467-022-05816-7","article-title":"What is the true burden of chronic kidney disease in children worldwide","volume":"38","author":"Harambat","year":"2023","journal-title":"Pediatr Nephrol"},{"key":"2025060923364830800_CIT0003","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s12325-021-01927-z","article-title":"A narrative review of chronic kidney disease in clinical practice: current challenges and future perspectives","volume":"39","author":"Evans","year":"2022","journal-title":"Adv Ther"},{"key":"2025060923364830800_CIT0004","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.1007\/s12325-023-02608-9","article-title":"Global economic burden associated with chronic kidney disease: a pragmatic review of medical costs for the inside CKD research programme","volume":"40","author":"Jha","year":"2023","journal-title":"Adv Ther"},{"key":"2025060923364830800_CIT0005","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ekir.2023.10.006","article-title":"Updates on new therapies for patients with CKD","volume":"9","author":"Tarun","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2025060923364830800_CIT0006","doi-asserted-by":"publisher","first-page":"2515690X221079688","DOI":"10.1177\/2515690X221079688","article-title":"Promoting plant-based therapies for chronic kidney disease","volume":"27","author":"Khan","year":"2022","journal-title":"J Evid Based Integr Med"},{"key":"2025060923364830800_CIT0007","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1517\/14728214.2014.900044","article-title":"Emerging drugs for chronic kidney disease","volume":"19","author":"Stefoni","year":"2014","journal-title":"Expert Opin Emerg Drugs"},{"key":"2025060923364830800_CIT0008","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discovery"},{"key":"2025060923364830800_CIT0009","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1016\/j.drudis.2019.06.014","article-title":"Drug repurposing: a promising tool to accelerate the drug discovery process","volume":"24","author":"Parvathaneni","year":"2019","journal-title":"Drug Discov Today"},{"key":"2025060923364830800_CIT0010","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.3390\/biomedicines10102458","article-title":"SGLT2 inhibitors in chronic kidney disease: from mechanisms to clinical practice","volume":"10","author":"Skrabic","year":"2022","journal-title":"Biomedicines"},{"key":"2025060923364830800_CIT0011","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2337\/dbi20-0040","article-title":"SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation","volume":"70","author":"Tuttle","year":"2021","journal-title":"Diabetes"},{"key":"2025060923364830800_CIT0012","doi-asserted-by":"publisher","first-page":"1479164120953625","DOI":"10.1177\/1479164120953625","article-title":"Risk of orthostatic hypotension associated with sodium-glucose cotransporter-2 inhibitor treatment: a meta-analysis of randomized controlled trials","volume":"17","author":"Rong","year":"2020","journal-title":"Diab Vasc Dis Res"},{"key":"2025060923364830800_CIT0013","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1208\/s12248-012-9390-1","article-title":"Drug repurposing: far beyond new targets for old drugs","volume":"14","author":"Oprea","year":"2012","journal-title":"AAPS J"},{"key":"2025060923364830800_CIT0014","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1016\/j.csbj.2023.07.007","article-title":"Drug repurposing screens to identify potential drugs for chronic kidney disease by targeting prostaglandin E2 receptor","volume":"21","author":"Huang","year":"2023","journal-title":"Comput Struct Biotechnol J"},{"key":"2025060923364830800_CIT0015","doi-asserted-by":"publisher","first-page":"e13435","DOI":"10.1111\/obr.13435","article-title":"Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus\u2014a systematic review and meta-analysis of randomized control trials","volume":"23","author":"Iqbal","year":"2022","journal-title":"Obes Rev"},{"key":"2025060923364830800_CIT0016","doi-asserted-by":"publisher","first-page":"115","DOI":"10.4236\/jdm.2021.114009","article-title":"Comparative review of drugs used in diabetes mellitus\u2014new and old","volume":"11","author":"Haq","year":"2021","journal-title":"J Diabetes Mellit"},{"key":"2025060923364830800_CIT0017","doi-asserted-by":"publisher","first-page":"111454","DOI":"10.1016\/j.biopha.2021.111454","article-title":"Mechanism and application of metformin in kidney diseases: An update","volume":"138","author":"Song","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"2025060923364830800_CIT0018","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11892-021-01442-z","article-title":"Renal protection with SGLT2 inhibitors: effects in acute and chronic kidney disease","volume":"22","author":"Bailey","year":"2022","journal-title":"Curr Diab Rep"},{"key":"2025060923364830800_CIT0019","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.amjmed.2018.12.010","article-title":"Potential dangers of serum urate-lowering therapy","volume":"132","author":"Perez-Gomez","year":"2019","journal-title":"Am J Med"},{"issue":"12","key":"2025060923364830800_CIT0020","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11906-017-0793-3","article-title":"The effect of xanthine oxidase inhibitors on blood pressure and renal function","volume":"19","author":"Bove","year":"2017","journal-title":"Curr Hypertens Rep"},{"key":"2025060923364830800_CIT0021","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/ndt\/gfx377","article-title":"JAK1\/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial","volume":"33","author":"Tuttle","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2025060923364830800_CIT0022","doi-asserted-by":"publisher","first-page":"7140","DOI":"10.1038\/s41598-022-10777-w","article-title":"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database","volume":"12","author":"Hoisnard","year":"2022","journal-title":"Sci Rep"},{"issue":"7","key":"2025060923364830800_CIT0023","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1172\/jci98814","article-title":"JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies","volume":"128","author":"Sanchez","year":"2018","journal-title":"J Clin Invest"},{"key":"2025060923364830800_CIT0024","doi-asserted-by":"publisher","first-page":"728089","DOI":"10.3389\/fmed.2021.728089","article-title":"Effects of SGLT2 inhibitors on renal outcomes in patients with chronic kidney disease: a meta-analysis","volume":"8","author":"Li","year":"2021","journal-title":"Front Med"},{"key":"2025060923364830800_CIT0025","doi-asserted-by":"publisher","first-page":"R200","DOI":"10.1530\/EC-21-0130","article-title":"How glucagon-like peptide 1 receptor agonists work","volume":"10","author":"Andreasen","year":"2021","journal-title":"Endocr Connect"},{"key":"2025060923364830800_CIT0026","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.3390\/cancers14133220","article-title":"The mechanism of action of biguanides: new answers to a complex question","volume":"14","author":"Di Magno","year":"2022","journal-title":"Cancers"},{"key":"2025060923364830800_CIT0027","doi-asserted-by":"publisher","first-page":"5416","DOI":"10.18632\/oncotarget.23387","article-title":"Effect of metformin on kidney function in patients with type 2 diabetes mellitus and moderate chronic kidney disease","volume":"9","author":"Hsu","year":"2018","journal-title":"Oncotarget"},{"key":"2025060923364830800_CIT0028","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/14740338.2019.1594771","article-title":"Safety and tolerability of available urate-lowering drugs: a critical review","volume":"18","author":"Strilchuk","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"2025060923364830800_CIT0029","doi-asserted-by":"publisher","first-page":"e2215878","DOI":"10.1001\/jamanetworkopen.2022.15878","article-title":"Association of uric acid-lowering therapy with incident chronic kidney disease","volume":"5","author":"Hassan","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025060923364830800_CIT0030","doi-asserted-by":"publisher","first-page":"1233259","DOI":"10.3389\/fcell.2023.1233259","article-title":"JAK\/STAT signaling in diabetic kidney disease","volume":"11","author":"Liu","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"2025060923364830800_CIT0031","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2017.88","article-title":"Chronic kidney disease","volume":"3","author":"Romagnani","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"2025060923364830800_CIT0032","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1681\/ASN.2021050680","article-title":"Decreased renal gluconeogenesis is a hallmark of chronic kidney disease","volume":"33","author":"Verissimo","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2025060923364830800_CIT0033","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.2215\/cjn.16831221","article-title":"Potential mechanisms involved in chronic kidney disease of unclear etiology","volume":"17","author":"Holliday Jr","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025060923364830800_CIT0034","doi-asserted-by":"publisher","first-page":"103942","DOI":"10.1016\/j.ebiom.2022.103942","article-title":"Hypoxia and chronic kidney disease","volume":"77","author":"Wang","year":"2022","journal-title":"EBioMedicine"},{"key":"2025060923364830800_CIT0035","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/ejhf.2814","article-title":"Inotropic therapy in patients with advanced heart failure. A clinical consensus statement from the Heart Failure Association of the European Society of Cardiology","volume":"25","author":"Gustafsson","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2025060923364830800_CIT0036","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1124\/jpet.112.193961","article-title":"Levosimendan protection against kidney ischemia\/reperfusion injuries in anesthetized pigs","volume":"342","author":"Grossini","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"2025060923364830800_CIT0037","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.toxrep.2019.02.006","article-title":"Effect of levosimendan, a calcium sensitizer, on cisplatin-induced nephrotoxicity in rats","volume":"6","author":"Abdelrahman","year":"2019","journal-title":"Toxicol Rep"},{"key":"2025060923364830800_CIT0038","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/ejhf.9","article-title":"Levosimendan improves renal function in acute decompensated heart failure: possible underlying mechanisms","volume":"16","author":"Fedele","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2025060923364830800_CIT0039","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1053\/j.ajkd.2015.09.015","article-title":"Levosimendan for prevention of acute kidney injury after cardiac surgery: a meta-analysis of randomized controlled trials","volume":"67","author":"Zhou","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"2025060923364830800_CIT0040","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1053\/j.jvca.2018.02.039","article-title":"Effect of levosimendan on renal outcome in cardiac surgery patients with chronic kidney disease and perioperative cardiovascular dysfunction: a substudy of a multicenter randomized trial","volume":"32","author":"Zangrillo","year":"2018","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"2025060923364830800_CIT0041","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jcrc.2019.12.022","article-title":"Effects of milrinone on renal perfusion, filtration, and oxygenation in patients with acute heart failure and low cardiac output early after cardiac surgery","volume":"57","author":"Lannemyr","year":"2020","journal-title":"J Crit Care"},{"key":"2025060923364830800_CIT0042","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1080\/08941939.2017.1343880","article-title":"Investigation of the effect of milrinone on renal damage in an experimental non-heart beating donor model","volume":"31","author":"Uysal","year":"2018","journal-title":"J Invest Surg"},{"key":"2025060923364830800_CIT0043","doi-asserted-by":"publisher","first-page":"136","DOI":"10.4097\/kjae.2014.66.2.136","article-title":"Effect of milrinone on the inflammatory response and NF-kB activation in renal ischemia-reperfusion injury in mice","volume":"66","author":"Jung","year":"2014","journal-title":"Korean J Anesthesiol"},{"key":"2025060923364830800_CIT0044","doi-asserted-by":"publisher","first-page":"D12","DOI":"10.1093\/eurheartj\/suaa091","article-title":"Differential effects of inotropes and inodilators on renal function in acute cardiac care","volume":"22","author":"Zima","year":"2020","journal-title":"Eur Heart J Suppl"},{"key":"2025060923364830800_CIT0045","doi-asserted-by":"publisher","first-page":"113391","DOI":"10.1016\/j.biopha.2022.113391","article-title":"The importance of pharmacokinetics, pharmacodynamic, and repetitive use of levosimendan","volume":"153","author":"Grze\u015bk","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"2025060923364830800_CIT0046","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10557-024-07614-9","article-title":"Levosimendan: a new therapeutical strategy in patients with renal insufficiency","author":"Liu","year":"2024","journal-title":"Cardiovasc Drugs Ther"},{"key":"2025060923364830800_CIT0047","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.3390\/ijms24043427","article-title":"Endothelin receptor antagonists in kidney disease","volume":"24","author":"Mart\u00ednez-D\u00edaz","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2025060923364830800_CIT0048","article-title":"Physiology, endothelin","volume-title":"StatPearls [Internet]","author":"Titus","year":"2023"},{"key":"2025060923364830800_CIT0049","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41569-019-0176-3","article-title":"Endothelins in cardiovascular biology and therapeutics","volume":"16","author":"Dhaun","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"2025060923364830800_CIT0050","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1177\/1753465817696040","article-title":"Ambrisentan: a review of its use in pulmonary arterial hypertension","volume":"11","author":"Rivera-Lebron","year":"2017","journal-title":"Ther Adv Respir Dis"},{"key":"2025060923364830800_CIT0051","doi-asserted-by":"publisher","first-page":"547","DOI":"10.4149\/BLL_2020_091","article-title":"Comparison of the protective effects of selective endothelin-a receptor antagonist, ambrisentan, and dual endothelin-A\/B receptor antagonist, bosentan, in experimental renal ischemia-reperfusion injury","volume":"121","author":"Kaz\u0131mo\u011flu","year":"2020","journal-title":"Bratisl Lek Listy"},{"key":"2025060923364830800_CIT0052","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1681\/ASN.2016070711","article-title":"Long-term endothelin-A receptor antagonism provides robust renal protection in humanized sickle cell disease mice","volume":"28","author":"Kasztan","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2025060923364830800_CIT0053","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40256-020-00426-w","article-title":"Efficacy and safety of long-term oral bosentan in different types of pulmonary arterial hypertension: a systematic review and meta-analysis","volume":"21","author":"Kuang","year":"2021","journal-title":"Am J Cardiovasc Drugs"},{"key":"2025060923364830800_CIT0054","doi-asserted-by":"publisher","first-page":"e6373","DOI":"10.1590\/1414-431X20176373","article-title":"Endothelin-1 receptor antagonists protect the kidney against the nephrotoxicity induced by cyclosporine-A in normotensive and hypertensive rats","volume":"51","author":"Caires","year":"2017","journal-title":"Br J Med Biol Res"},{"key":"2025060923364830800_CIT0055","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ejphar.2014.03.002","article-title":"Selective ETA receptor blockade protects against cisplatin-induced acute renal failure in male rats","volume":"730","author":"Helmy","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"2025060923364830800_CIT0056","doi-asserted-by":"publisher","first-page":"7180","DOI":"10.1007\/s11356-020-11035-0","article-title":"Ameliorative role of bosentan, an endothelin receptor antagonist, against sodium arsenite-induced renal dysfunction in rats","volume":"28","author":"Sharma","year":"2021","journal-title":"Environ Sci Pollut Res"},{"key":"2025060923364830800_CIT0057","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3892\/br.2016.832","article-title":"Effect of bosentan is correlated with MMP\u20119\/TIMP\u20111 ratio in bleomycin\u2011induced pulmonary fibrosis","volume":"6","author":"Zuo","year":"2017","journal-title":"Biomed Rep"},{"key":"2025060923364830800_CIT0058","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.cca.2020.03.008","article-title":"The endothelin system as target for therapeutic interventions in cardiovascular and renal disease","volume":"506","author":"Eroglu","year":"2020","journal-title":"Clin Chim Acta"},{"key":"2025060923364830800_CIT0059","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/apm.12667","article-title":"Citrate attenuates vascular calcification in chronic renal failure rats","volume":"125","author":"Ou","year":"2017","journal-title":"APMIS"},{"key":"2025060923364830800_CIT0060","doi-asserted-by":"publisher","first-page":"822178","DOI":"10.3389\/fphar.2022.822178","article-title":"Efficacy of osteoporosis medications for patients with chronic kidney disease: an updated systematic review and network meta-analysis","volume":"13","author":"Chen","year":"2022","journal-title":"Front Pharmacol"},{"key":"2025060923364830800_CIT0061","doi-asserted-by":"publisher","first-page":"40534","DOI":"10.1038\/srep40534","article-title":"Persistent fibroblast growth factor 23 signalling in the parathyroid glands for secondary hyperparathyroidism in mice with chronic kidney disease","volume":"7","author":"Kawakami","year":"2017","journal-title":"Sci Rep"},{"key":"2025060923364830800_CIT0062","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1111\/bcp.13867","article-title":"Pharmacology of bisphosphonates","volume":"85","author":"Cremers","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"2025060923364830800_CIT0063","doi-asserted-by":"publisher","first-page":"172773","DOI":"10.1016\/j.ejphar.2019.172773","article-title":"Bisphosphonates\u2014much more than only drugs for bone diseases","volume":"866","author":"Ku\u017anik","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"2025060923364830800_CIT0064","doi-asserted-by":"publisher","first-page":"115751","DOI":"10.1016\/j.bone.2020.115751","article-title":"Is there a role for bisphosphonates in vascular calcification in chronic kidney disease","volume":"142","author":"Hildebrand","year":"2021","journal-title":"Bone"},{"key":"2025060923364830800_CIT0065","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12882-017-0478-9","article-title":"Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trials","volume":"18","author":"Shigematsu","year":"2017","journal-title":"BMC Nephrol"},{"key":"2025060923364830800_CIT0066","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1007\/s00774-018-0977-1","article-title":"Efficacy and safety of once-monthly risedronate in osteoporosis subjects with mild-to-moderate chronic kidney disease: a post hoc subgroup analysis of a phase III trial in Japan","volume":"37","author":"Sugimoto","year":"2019","journal-title":"J Bone Miner Metab"},{"key":"2025060923364830800_CIT0067","first-page":"3","article-title":"Effect and safety of alendronate on bone density in patients with chronic kidney disease; a controlled double-blind randomized clinical trial","volume":"4","author":"Shahbazian","year":"2016","journal-title":"J Parathyr Dis"},{"key":"2025060923364830800_CIT0068","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1111\/bcp.14780","article-title":"Bisphosphonate nephropathy: a case series and review of the literature","volume":"87","author":"de Roij van Zuijdewijn","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"2025060923364830800_CIT0069","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/ddr.21760","article-title":"Role of mineralocorticoid receptor antagonists in kidney diseases","volume":"82","author":"Patel","year":"2021","journal-title":"Drug Dev Res"},{"key":"2025060923364830800_CIT0070","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.kint.2019.02.030","article-title":"Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis","volume":"96","author":"Barrera-Chimal","year":"2019","journal-title":"Kidney Int"},{"key":"2025060923364830800_CIT0071","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1681\/ASN.2022020207","article-title":"Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized crossover clinical trial","volume":"33","author":"Provenzano","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2025060923364830800_CIT0072","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1111\/dom.15518","article-title":"Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: a multicentre, randomized, double-blind, placebo-controlled, Phase I trial","volume":"26","author":"Bornstein","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2025060923364830800_CIT0073","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"2025060923364830800_CIT0074","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/17512433.2022.2094770","article-title":"Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes","volume":"15","author":"Lerman","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2025060923364830800_CIT0075","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10157-023-02413-2","article-title":"The role of a novel mineralocorticoid receptor antagonist, finerenone, in chronic kidney disease: mechanisms and clinical advances","volume":"28","author":"Chen","year":"2024","journal-title":"Clin Exp Nephrol"},{"key":"2025060923364830800_CIT0076","doi-asserted-by":"publisher","first-page":"107701","DOI":"10.1016\/j.pharmthera.2020.107701","article-title":"Mineralocorticoid receptor antagonists in patients with chronic kidney disease","volume":"219","author":"Cosimato","year":"2021","journal-title":"Pharmacol Ther"},{"key":"2025060923364830800_CIT0077","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.kisu.2021.11.005","article-title":"Clinical perspective\u2014evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes","volume":"12","author":"Rossing","year":"2022","journal-title":"Kidney Int Suppl"},{"key":"2025060923364830800_CIT0078","doi-asserted-by":"publisher","first-page":"5215","DOI":"10.1096\/fj.201800205R","article-title":"DNA methylation and the potential role of demethylating agents in prevention of progressive chronic kidney disease","volume":"32","author":"Larkin","year":"2018","journal-title":"FASEB J"},{"key":"2025060923364830800_CIT0079","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3390\/genes11070811","article-title":"DNA methylation dysfunction in chronic kidney disease","volume":"11","author":"Ingrosso","year":"2020","journal-title":"Genes"},{"key":"2025060923364830800_CIT0080","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1038\/s41401-022-00898-3","article-title":"Dihydroartemisinin suppresses renal fibrosis in mice by inhibiting DNA-methyltransferase 1 and increasing Klotho","volume":"43","author":"Zhou","year":"2022","journal-title":"Acta Pharmacol Sin"},{"key":"2025060923364830800_CIT0081","doi-asserted-by":"publisher","first-page":"11474","DOI":"10.1096\/fj.201902957rr","article-title":"Hydrogen sulfide attenuates renal fibrosis by inducing TET-dependent DNA demethylation on klotho promoter","volume":"34","author":"Gu","year":"2020","journal-title":"FASEB J"},{"key":"2025060923364830800_CIT0082","doi-asserted-by":"publisher","first-page":"e15961","DOI":"10.14814\/phy2.15961","article-title":"NRF2 in kidney physiology and disease","volume":"12","author":"Bondi","year":"2024","journal-title":"Physiol Rep"},{"key":"2025060923364830800_CIT0083","doi-asserted-by":"publisher","first-page":"5440","DOI":"10.1002\/ptr.7176","article-title":"Sulforaphane: a review of its therapeutic potentials, advances in its nanodelivery, recent patents, and clinical trials","volume":"35","author":"Mangla","year":"2021","journal-title":"Phytother Res"},{"key":"2025060923364830800_CIT0084","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13765-024-00858-x","article-title":"Sulforaphane (Sul) reduces renal interstitial fibrosis (RIF) by controlling the inflammation and TGF-\u03b2\/Smad signaling pathway","volume":"67","author":"Yu","year":"2024","journal-title":"Appl Biol Chem"},{"key":"2025060923364830800_CIT0085","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.freeradbiomed.2023.12.022","article-title":"Sulforaphane protects from kidney damage during the release of unilateral ureteral obstruction (RUUO) by activating nuclear factor erythroid 2-related factor 2 (Nrf2): role of antioxidant, anti-inflammatory, and antiapoptotic mechanisms","volume":"212","author":"Aranda-Rivera","year":"2024","journal-title":"Free Radic Biol Med"},{"key":"2025060923364830800_CIT0086","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.freeradbiomed.2024.05.034","article-title":"Sulforaphane upregulates the mRNA expression of NRF2 and NQO1 in non-dialysis patients with chronic kidney disease","volume":"221","author":"Ribeiro","year":"2024","journal-title":"Free Radic Biol Med"},{"key":"2025060923364830800_CIT0087","doi-asserted-by":"publisher","first-page":"121664","DOI":"10.1016\/j.lfs.2023.121664","article-title":"Sulforaphane exhibits potent renoprotective effects in preclinical models of kidney diseases: a systematic review and meta-analysis","volume":"322","author":"Monteiro","year":"2023","journal-title":"Life Sci"},{"key":"2025060923364830800_CIT0088","doi-asserted-by":"publisher","first-page":"115617","DOI":"10.1016\/j.biopha.2023.115617","article-title":"CDDO-Me ameliorates podocyte injury through anti-oxidative stress and regulation of actin cytoskeleton in adriamycin nephropathy","volume":"167","author":"Xu","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"2025060923364830800_CIT0089","doi-asserted-by":"publisher","first-page":"6053","DOI":"10.3390\/ijms24076053","article-title":"Insights into the molecular mechanisms of NRF2 in kidney injury and diseases","volume":"24","author":"Lin","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2025060923364830800_CIT0090","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.coph.2019.02.009","article-title":"Role of the P2X7 receptor in the pathogenesis of type 2 diabetes and its microvascular complications","volume":"47","author":"Solini","year":"2019","journal-title":"Curr Opin Pharmacol"},{"key":"2025060923364830800_CIT0091","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41419-020-03384-y","article-title":"P2X7 receptor signaling promotes inflammation in renal parenchymal cells suffering from ischemia-reperfusion injury","volume":"12","author":"Qian","year":"2021","journal-title":"Cell Death Dis"},{"key":"2025060923364830800_CIT0092","doi-asserted-by":"publisher","first-page":"117640","DOI":"10.1016\/j.lfs.2020.117640","article-title":"Inhibition of the P2X7 receptor improves renal function via renin-angiotensin system and nitric oxide on diabetic nephropathy in rats","volume":"251","author":"Nascimento","year":"2020","journal-title":"Life Sci"},{"key":"2025060923364830800_CIT0093","doi-asserted-by":"publisher","first-page":"102102","DOI":"10.1016\/j.jsps.2024.102102","article-title":"Antifibrotic effect of the P2X7 receptor antagonist A740003 against acute myocardial infarction-induced fibrotic remodelling","volume":"32","author":"Almusallam","year":"2024","journal-title":"Saudi Pharm J"},{"key":"2025060923364830800_CIT0094","doi-asserted-by":"publisher","first-page":"14914","DOI":"10.1002\/jcp.28325","article-title":"Berberine as a potential autophagy modulator","volume":"234","author":"Mohammadinejad","year":"2019","journal-title":"J Cell Physiol"},{"key":"2025060923364830800_CIT0095","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1038\/s41401-019-0263-3","article-title":"Podoplanin mediates the renoprotective effect of berberine on diabetic kidney disease in mice","volume":"40","author":"Yu","year":"2019","journal-title":"Acta Pharmacol Sin"},{"key":"2025060923364830800_CIT0096","doi-asserted-by":"publisher","first-page":"106481","DOI":"10.1016\/j.phrs.2022.106481","article-title":"Protective effect of berberine in diabetic nephropathy: a systematic review and meta-analysis revealing the mechanism of action","volume":"185","author":"Hu","year":"2022","journal-title":"Pharmacol Res"},{"key":"2025060923364830800_CIT0097","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.2147\/DDDT.S317776","article-title":"Effect of berberine on hyperuricemia and kidney injury: a network pharmacology analysis and experimental validation in a mouse model","volume":"15","author":"Li","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"2025060923364830800_CIT0098","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/j.apsb.2022.12.010","article-title":"Berberine ameliorates chronic kidney disease through inhibiting the production of gut-derived uremic toxins in the gut microbiota","volume":"13","author":"Pan","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"2025060923364830800_CIT0099","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1080\/13543784.2018.1493455","article-title":"Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease","volume":"27","author":"Del Vecchio","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"2025060923364830800_CIT0100","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.kint.2016.07.019","article-title":"Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease","volume":"90","author":"Pergola","year":"2016","journal-title":"Kidney Int"},{"key":"2025060923364830800_CIT0101","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.34067\/KID.0000000567","article-title":"Safety and efficacy of vadadustat once-daily and 3-times-weekly in dialysis-dependent chronic kidney disease patients with anemia","volume":"5","author":"Kooienga","year":"2024","journal-title":"Kidney360"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/77\/6\/715\/61520885\/rgaf002.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/77\/6\/715\/61520885\/rgaf002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T03:36:53Z","timestamp":1749526613000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/77\/6\/715\/7964751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,20]]},"references-count":101,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,1,20]]},"published-print":{"date-parts":[[2025,6,9]]}},"URL":"https:\/\/doi.org\/10.1093\/jpp\/rgaf002","relation":{},"ISSN":["0022-3573","2042-7158"],"issn-type":[{"value":"0022-3573","type":"print"},{"value":"2042-7158","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,1,20]]}}}